Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
Abstract Background Compounds in clinical development for nonalcoholic steatohepatitis (NASH) improve liver histopathology in diet-induced obese mouse models of biopsy-confirmed NASH. Since the biopsy section used for histopathological evaluation represents only < 1% of the whole mouse liver, we...
Main Authors: | Maria Nicoline Baandrup Kristiansen, Sanne Skovgård Veidal, Christina Christoffersen, Michael Feigh, Niels Vrang, Jonathan David Roth, Mary Erickson, Luciano Adorini, Jacob Jelsing |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12876-019-1149-z |
Similar Items
-
Histological findings and NAFLD/NASH Status in liver biopsies of patients subjected to bariatric surgery
by: Marielle Malucelli, et al.
Published: (2023-11-01) -
Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
by: Nikolaos Perakakis, et al.
Published: (2021-06-01) -
Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
by: D.N. Amarapurkar, et al.
Published: (2006-01-01) -
Comparison of liver enzymes level and sonographic findings value with liver biopsy findings in nonalcoholic fatty liver disease patients
by: Mahsa Khodadoostan, et al.
Published: (2016-01-01) -
The role of the microbiome in NAFLD and NASH
by: Aleksandra A Kolodziejczyk, et al.
Published: (2019-02-01)